Comments on: Cell Therapeutics Teeters on the Brink as Cash Runs Out on Promising Cancer Drugs http://www.xconomy.com/seattle/2009/02/13/cell-therapeutics-teeters-on-the-brink-as-cash-runs-out-on-promising-cancer-drugs/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 03:54:18 +0000 hourly 1 http://wordpress.org/?v=3.0.4 By: Cell Therapeutics: The MJ of Biotech | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Research, Humor and Updates on the Latest Events in Biotech and Pharma - Unique, Insightful, Truthful, Sometimes Sneaky http://www.xconomy.com/seattle/2009/02/13/cell-therapeutics-teeters-on-the-brink-as-cash-runs-out-on-promising-cancer-drugs/comment-page-1/#comment-67485 Cell Therapeutics: The MJ of Biotech | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Research, Humor and Updates on the Latest Events in Biotech and Pharma - Unique, Insightful, Truthful, Sometimes Sneaky Fri, 26 Jun 2009 19:16:56 +0000 http://www.xconomy.com/?p=12612#comment-67485 [...] has been riddled in controversy for years. As Xconomy said, there was the corporate jet issues, Bianco using CTIC funds, a failed boardroom coup against [...] [...] has been riddled in controversy for years. As Xconomy said, there was the corporate jet issues, Bianco using CTIC funds, a failed boardroom coup against [...]

]]> By: MedCity morning read, Monday, Feb. 16 : MedCity News http://www.xconomy.com/seattle/2009/02/13/cell-therapeutics-teeters-on-the-brink-as-cash-runs-out-on-promising-cancer-drugs/comment-page-1/#comment-46512 MedCity morning read, Monday, Feb. 16 : MedCity News Mon, 16 Feb 2009 14:25:01 +0000 http://www.xconomy.com/?p=12612#comment-46512 [...] Cell Therapeutics teeters on the brink as cash runs out on promising cancer drugs(Xconomy) [...] [...] Cell Therapeutics teeters on the brink as cash runs out on promising cancer drugs(Xconomy) [...]

]]> By: clambottler http://www.xconomy.com/seattle/2009/02/13/cell-therapeutics-teeters-on-the-brink-as-cash-runs-out-on-promising-cancer-drugs/comment-page-1/#comment-46201 clambottler Fri, 13 Feb 2009 16:28:51 +0000 http://www.xconomy.com/?p=12612#comment-46201 "The company now hopes shareholders will approve a transaction at a Feb. 27 meeting that will clear much of the debt off its books, Bianco says." I have heard that they have recently submitted a shareholder meeting request for an additional 400 million authorized shares together with an up to 1 share for 20 reverse split. Is the transaction you refer to ? So if they authorize another 400 million shares and then do a reverse split that will clear up the debt ? “The company now hopes shareholders will approve a transaction at a Feb. 27 meeting that will clear much of the debt off its books, Bianco says.”

I have heard that they have recently submitted a shareholder meeting request for an additional 400 million authorized shares together with an up to 1 share for 20 reverse split. Is the transaction you refer to ?

So if they authorize another 400 million shares and then do a reverse split that will clear up the debt ?

]]> By: clambottler http://www.xconomy.com/seattle/2009/02/13/cell-therapeutics-teeters-on-the-brink-as-cash-runs-out-on-promising-cancer-drugs/comment-page-1/#comment-46193 clambottler Fri, 13 Feb 2009 15:56:13 +0000 http://www.xconomy.com/?p=12612#comment-46193 I find it strange that you choose these words "What’s striking is that Cell Therapeutics is sitting on two drugs for non-Hodgkin’s lymphoma that are on the cusp of critical milestones that could turn them into moneymaking products." RIT owns Zevalin. CTIC has a 50 % stake in Zevalin; Spectrum owns the other 50 %. CTIC has negotiated an option to sell their 50 % stake to Spectrum for 18 million dollars. And I believe you will find Biogen is still owed Royalty and Milestone. I do not know if that is "sitting" on a drug. Perhaps it is. I find it strange that you choose these words “What’s striking is that Cell Therapeutics is sitting on two drugs for non-Hodgkin’s lymphoma that are on the cusp of critical milestones that could turn them into moneymaking products.”

RIT owns Zevalin. CTIC has a 50 % stake in Zevalin; Spectrum owns the other 50 %. CTIC has negotiated an option to sell their 50 % stake to Spectrum for 18 million dollars. And I believe you will find Biogen is still owed Royalty and Milestone.

I do not know if that is “sitting” on a drug. Perhaps it is.

]]> By: clambottler http://www.xconomy.com/seattle/2009/02/13/cell-therapeutics-teeters-on-the-brink-as-cash-runs-out-on-promising-cancer-drugs/comment-page-1/#comment-46192 clambottler Fri, 13 Feb 2009 15:51:27 +0000 http://www.xconomy.com/?p=12612#comment-46192 You fail to mention all the previously terminated trials of pixantrone; here are a few: Terminated Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL Terminated Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma Terminated A Trial in Patients With Diffuse Large-B-Cell Lymphoma Comparing Pixantrone Against Doxorubicin You fail to mention the "current" EXTEND trial that you speak so highly of is a SPA trial designed for 320 patients. Estimated Enrollment: 320 Study Start Date: July 2004 While mentioning 140 patients in the current trial (when viewing design and power you may notice less then 1/2 were enrolled) --- I believe CTIC had mentioned that 97 were evaluable. So you have less then 1/2 to 1/3 the evaluable patients. How do you think that will effect the power ? Finally you might want to review the fact that I believe it was 140 patients enrolled in 130 centers; worldwide. In my opinion 1 patient per trial site leaves room for questions; and perhaps should be looked at with a hard eye. You fail to mention all the previously terminated trials of pixantrone; here are a few:

Terminated Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Terminated Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin’s Lymphoma

Terminated A Trial in Patients With Diffuse Large-B-Cell Lymphoma Comparing Pixantrone Against Doxorubicin

You fail to mention the “current” EXTEND trial that you speak so highly of is a SPA trial designed for 320 patients.

Estimated Enrollment: 320
Study Start Date: July 2004

While mentioning 140 patients in the current trial (when viewing design and power you may notice less then 1/2 were enrolled) — I believe CTIC had mentioned that 97 were evaluable. So you have less then 1/2 to 1/3 the evaluable patients. How do you think that will effect the power ?

Finally you might want to review the fact that I believe it was 140 patients enrolled in 130 centers; worldwide. In my opinion 1 patient per trial site leaves room for questions; and perhaps should be looked at with a hard eye.

]]>